Posted by Michael Wonder on 07 Jan 2026
Maviret receives Health Canada approval for the treatment of acute hepatitis C virus
6 January 2026 - Maviret received approval through Health Canada's priority review process, based on data from the Phase 3 M20-350 trial establishing it to be a highly efficacious treatment for people with acute hepatitis C.
AbbVie announced today that Health Canada has approved Maviret (glecaprevir/pibrentasvir tablets) for the treatment of acute and chronic hepatitis C virus infection in adults and paediatric patients 3 years of age and older and weighing ≥12 kg.
